Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL [Phase 1]
Phase 1 trial evaluating acalabrutinib with anti-CD20 therapy and venetoclax in relapsed/refractory or untreated chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating cytokine-treated veto cells as an adoptive therapy after stem cell transplantation for various hematolog…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL [Phase 2]
An update on a Phase II trial evaluating MOR00208 in combination with lenalidomide for relapsed/refractory or untreated older patients with …
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 [Phase 1]
This document reports an extension-phase study of UC-961 (cirmtuzumab) in patients with chronic lymphocytic leukemia; results have been post…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax [Phase 1, Phase 2]
A Phase 1/2 trial evaluating pirtobrutinib (LOXO-305) as consolidation to eradicate minimal residual disease in chronic lymphocytic leukemia…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas [Phase 1]
Phase 1 clinical trial update for ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select …
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
This completed clinical trial evaluates the safety and effectiveness of Venetoclax for patients with chronic lymphocytic leukemia in routine…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy
This clinical trial update reports on refractoriness to ibrutinib, a Bruton Tyrosine Kinase inhibitor, and to systemic targeted therapies in…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial of acalabrutinib for untreated chronic lymphocytic leukemia is ongoing. The study status is currently active but not recruit…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients [Phase 3]
Acalabrutinib safety study in untreated and relapsed or refractory chronic lymphocytic leukemia patients (Phase 3) has completed.
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating a risk-adapted, MRD-driven strategy in untreated, fit patients with intermediate-risk chronic lymphocytic leukemia …
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Phase II Trial GA101 Inbrutinib B CLL [Phase 2]
Phase II trial GA101 (obinutuzumab) in combination with ibrutinib for chronic lymphocytic leukemia has completed. The study was sponsored by…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A [Phase 2]
Phase 2 clinical trial update for preemptive therapy in high-risk chronic lymphocytic leukemia (Stage A); the study is currently active but …
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
A completed clinical trial evaluating how often adult chronic lymphocytic leukemia patients in Japan achieve undetectable minimal residual d…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
The update reports on biomarkers that may predict early failure of ibrutinib therapy in high-risk TP53-mutated chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer [Phase 1]
A Phase 1 trial evaluating natural killer cell therapy in combination with Interleukin-2 and the TGF-beta receptor I inhibitor vactosertib f…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study of BAFF CAR-T cells (LMY-920) for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma is curren…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). [Phase 2]
Phase II clinical trial update for a time-limited combination therapy (pirtobrutinib, venetoclax, obinutuzumab) in recurrent Chronic Lymphoc…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning before allogeneic donor stem cell transplantation in patients with high-risk hematol…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
Phase 2 clinical trial update assessing changes in disease activity and adverse events when oral venetoclax is combined with intravenous obi…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients [Phase 1]
Phase 1 study assessing rituximab plus high-dose methylprednisolone debulking before venetoclax in patients with chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) [Phase 2]
A Phase 2 clinical trial evaluating the combination of venetoclax and obinutuzumab in chronic lymphocytic leukemia is ongoing, with the stud…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL [Phase 1]
Phase 1 trial of JBH492 as monotherapy in chronic lymphocytic leukemia and non-Hodgkin lymphoma reports safety and preliminary efficacy; the…